News | June 02, 2021
Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
The GMP certificate is valid for three years until April 2024.
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The company plans to enter the EU markets in FY22
Subscribe To Our Newsletter & Stay Updated
